Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Authorised, recruitment pending
Participants planned
20
Countries
1
Sites
1
Osteoarthritis of the knee
Key facts
- Sponsor
- Centrexion Therapeutics Corp.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Musculoskeletal Diseases [C05]
- Decision date (initial)
- 2026-02-24
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Osteoarthritis of the knee
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 21.1 | LLT | 10023476 | Knee osteoarthritis | 10028395 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Centrexion Therapeutics Corp.
- Sponsor organisation
- Centrexion Therapeutics Corp.
- Address
- One Boston Place Suite 3520
- City
- Boston
- Postcode
- 02108-4407
- Country
- United States
Scientific contact point
- Organisation
- Centrexion Therapeutics Corp.
- Contact name
- Chief Scientific Officer at NBCD
Public contact point
- Organisation
- Centrexion Therapeutics Corp.
- Contact name
- Chief Scientific Officer at NBCD
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Denmark | Authorised, recruitment pending | 20 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-11-13 | Denmark | Acceptable 2026-02-20
|
2026-02-24 |